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INCREASE IN CD5+ B CELLS IN 
JUVENILE RHEUMATOID ARTHRITIS 
Relationship to IgM Rheumatoid Factor Expression and Disease Activity 
JAMES N. JARVIS, JOSEPH KAPLAN. and NANCY FINE 
Objective. To investigate the association between 
CD5+ B cell expression and IgM rheumatoid factor 
(IgM-RF) in juvenile rheumatoid arthritis (JRA). 
Methods. CD5+ B cell levels analyzed by flow 
cytometry and IgM-RF expression determined by enzyme- 
linked immunosorbent assay were compared in children 
with JRA, children with other collagen vascular dis- 
eases, and healthy controls. 
Results. Children with polyarticular JRA had 
expanded populations of CDS+ B cells, and expansion 
of CDS+ B cells and IgM-RF both correlated with 
disease activity. 
Conclusion. The results indicate that an ex- 
panded CD5+ B cell population leads to IgM-RF pro- 
duction in patients with polyarticular JRA, as well as 
patients with RA. 
The presence of IgM rheumatoid factors (IgM- 
RF) is a well-described feature of juvenile rheumatoid 
arthritis (JRA) (1). IgM-RF expression appears to 
correlate with disease activity in JRA (1,2), suggesting 
that IgM-RF plays a role in the pathogenesis of the 
disease. 
The main sources of IgM-RF are B cells that 
express the pan-T cell marker CD5 (Leu-1) (3,4). 
Expanded populations of these cells have been de- 
scribed in adult RA (5).  Whether the expression of 
CD5 on B cells is a marker for B cell activation or 
identifies a distinct cell lineage remains controversial (5). 
Although Martini et a1 have described elevated 
levels of CD5+ lymphocytes in children with JRA, all 
of the children they studied were negative for IgM-RF 
(presumably by the latex agglutination method) (6). 
However, several investigators (7,8) have shown that 
IgM-RF are commonly found in children with JRA 
when sensitive enzyme-linked immunosorbent assay 
(ELISA) techniques are used. We conducted the 
present study to test the hypothesis that expanded 
populations of CD5+ B cells occur in JRA and are 
associated with LgM-RF detected by ELISA. 
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PATIENTS AND METHODS 
Patients. The study subjects were children between 
the ages of 15 months and 10 years, who were attending the 
Rheumatology/Immunology Clinic at the Children’s Hospital 
of Michigan. Sixteen of the children (mean & SD age 6 ? 3.3 
years) had polyarticular JRA and 13 (age 3.7 * 2.3 years) had 
pauciarticular JRA (9). Eight children (age 7.6 t 3.4 years) 
with other collagen vascular diseases (5 with juvenile der- 
matomyositis and 1 each with systemic lupus erythemato- 
sus, ankylosing spondylitis, and uncharacterized myositid 
retinitis) were also included. Control subjects included 7 
children with nonspecific musculoskeletal complaints, 3 chil- 
dren referred for immunologic evaluation and subsequently 
shown to have normal immunologic functioning, and 13 
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healthy children. The mean age of the control subjects was 
4.2 * 2.9 years. 
All children studied had negative findings on latex 
agglutination tests for IgM-RF. All those with JRA were 
taking nonsteroidal antiinflammatory drugs at the time of 
study. In addition, 2 children with polyarticular disease were 
taking oral gold, at a dosage of 3.0 mg/day, and 2 children 
were receiving oral methotrexate, 5.0 mg weekly. 
Disease activity. Children with polyarticular JRA 
were considered to have active disease if they presented 
with warmth and effusion andlor synovial thickening of more 
than 3 joints. Children with pauciarticular disease were 
considered to have active disease if they presented with 
detectable warmth and synovial thickening in at least 1 joint. 
Antibodies. Monoclonal anti-CD5 conjugated with 
phycoerythrin (PE) and pan-B cell-specific monoclonal anti- 
CD20 conjugated with fluorescein isothiocyanate (FITC) 
were obtained from Coulter Immunology (Hialeah, FL). 
Human IgG for the I@-RF ELISA was obtained from 
Sigma (St. Louis, MO). 
Dual-fluorescence flow cytometry. One hundred mi- 
croliters of whole blood was incubated with 5.0 pl of 
PE-conjugated antLCD5 and 5.0 pl of FITC-conjugated 
anti-CD20. Cells were washed 3 times in phosphate buffered 
saline (PBS) and erythrocytes were lysed using a whole 
blood lysing kit (Coulter). The cells were then washed twice, 
resuspended in PBS, and analyzed by flow microfluorometry 
on an EPICS C flow cytometer, to determine the percentage 
of red- and/or green-stained lymphocytes gated by forward- 
angle and 90O-angle light-scattering. 
ELISA for IgM-RF. Serum from children with JRA or 
from controls was diluted 1: 100, and the ELISA for IgM-RF 
was performed as described by Moore et a1 (7). Plates were 
read at 405 nm and results were compared with a standard 
curve derived from control sera run at the same time. Optical 
density readings >2 standard deviations from the mean in 
the control group were considered to represent IgM-RF 
positivity. 
Statistical analysis. Differences between mean per- 
centages of CD5+ B cells were assessed by analysis of 
variance, using Scheffe’s F test or Fisher’s PLSD test. 
Chi-square analysis was used to examine the relationship 
between disease activity and the presence or absence of 
IgM-RFs. P values less than 0.05 were considered significant. 
RESULTS 
A comparison of the percentage of CD5+ B 
cells in the different study groups is shown in Figure 1.  
The mean 2 SD percentage of CD5+ B cells was 
significantly greater in children with polyarticular JRA 
(40.9 f 22%) than in children with other collagen 
vascular diseases (20.0 2 %) (P = 0.0143) or in 
healthy controls (22.1 ? 8%) (P = 0.0028). The level of 
circulating CDS+ B lymphocytes in children with 
pauciarticular JRA (27.5 f 9%) was intermediate 
between that of the children with polyarticular disease 
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Figure 1. Percentages of B cells expressing CD5, as determined by 
dual-fluorescence flow cytometry , in patients with polyarticular 
juvenile rheumatoid arthritis (JRA POLY), patients with pauciartic- 
ular JRA (JRA PAUCI), patients with other collagen vascular 
diseases (CVD), and healthy controls. For the JRA patients, squares 
indicate active disease and circles indicate inactive disease; closed 
symbols indicate IgM rheumatoid factor (IgM-RF) positivity by 
enzyme-linked immunosorbent assay (ELISA) and open symbols 
indicate IgM-RF negativity by ELISA. The mean percentage of 
CD5+ B cells (represented by horizontal lines) was significantly 
greater in children who had polyarticular JRA compared with 
children who had other collagen vascular diseases (P = 0.0143), with 
healthy controls (P = O.oOZS), and with children who had pauci- 
articular JRA (P < 0.05). Although the mean level of CD5+ B cells 
was higher in children with pauciarticular J R A  than in the control 
groups, the differences were not statistically significant. 
level among children with pauciarticular disease and 
that among children with polyarticular disease was 
also statistically significant (P < 0.05). 
Elevated levels of CD5+ B cells in children 
with polyarticular JRA occurred only in those with 
active disease. All but 1 of the 10 children with active 
polyarticular JRA had >30% CD5+ B cells, whereas 
none of the 6 children with inactive polyarticular JRA 
had levels this great. The mean f SD level of CD5+ B 
cells in children with active polyarticular JRA (53.0 * 
20%) (Table 1) was more than twice the average level 
in children with inactive polyarticular JRA (22.0 f 
5%); the level in the latter group was similar to that 
found in the healthy subjects. In children with pauci- 
articular JRA, there was no demonstrable correlation 
between disease activity and CD5+ B cell levels. 
IgM-RF was detected in 8 of the 16 children 
with polyarticular JRA, but was undetectable in any of 
the other children tested. Among the children with 
detectable IgM-RF, 7 of 8 had active disease. How- 
ever, 3 of the 10 children with active disease did not 
have detectable IgM-RF, and all 3 of these children 
206 JARVIS ET AL 
Table 1. CD5+ B cell IgM rheumatoid factor (IgM-RF) expres- 
sion, by disease activity, in patients with polyarticular and pauci- 
articular juvenile rheumatoid arthritis (JRA) 
No. with 
Group, % CD5+ B cells >30% No. with 
disease status (mean * SD) CD5+ B cells hidden RF 
Polyarticular JRA 
Active 53 * 20 9/10 7/10 
Inactive 22 5 5 016 116 
Active 26 * 9 1/10 0110 
Inactive 33 -t- 23 1 13 013 
Pauciarticular JRA 
had elevated levels of CD5+ B cells (Figure 1). Thus, 
although the presence of IgM-RF showed a significant 
association with disease activity in children with poly- 
articular JRA, it did not correlate with levels of CD5+ 
B cells. 
DISCUSSION 
This study was conducted to determine whether 
children with JRA have elevated levels of CDS+ B 
cells, and to determine whether these levels correlate 
with either disease activity or the presence of IgM-RF 
detected by ELISA. Our data show that, in compari- 
son with normal controls and children with other 
collagen vascular diseases, expanded populations of 
these cells are demonstrable in the circulation of 
patients with polyarticular JRA, but not those with 
pauciarticular JRA. 
Our control population was slightly younger 
than the group with polyarticular JRA, but the differ- 
ences in age among the 4 groups studied were not 
statistically significant. CD5+ B cell levels are high at 
birth (%loo% of B cells in cord blood are CD5+ [lo]) 
and tend to fall with age; thus, the slightly younger age 
of the healthy controls would, if anything, obscure, 
rather than artificially create, significant differences 
between their levels of CD5+ B cells and those in 
children with polyarticular disease. Although CD5+ B 
cell levels were also slightly increased in children with 
pauciarticular JRA compared with the healthy controls 
and the children with other collagen vascular diseases 
(28%, versus 20% in children with collagen vascular 
diseases and 22% in the controls), the differences were 
not significant. 
We have also shown that increases in circulat- 
ing levels of CDS+ B cells are strongly associated with 
active disease in polyarticular JRA. Increased levels in 
this patient group occurred only among children with 
active disease. Although Martini et al demonstrated 
that levels of circulating CD5+ B cells commonly 
change in children with JRA irrespective of disease 
activity (6), their patients were not divided by type of 
disease onset. Thus, the inclusion of patients with 
pauciarticular disease in an analysis of the relationship 
between CD5+ B cell levels and disease activity in 
JRA might have obscured the relationship demon- 
strated here, since these levels do not appear to vary 
with disease activity in pauciarticular disease as they 
do in polyarticular disease. 
A similar association between increased levels 
of CD5+ B cells and disease activity has not been 
reported in adult RA patients. Although individual 
adult patients with systemic lupus erythematosus and 
RA have been shown to have decreased levels of 
CD5+ B cells during periods of inactive disease (1 l), 
evidence suggests that CD5+ B cell levels in adults are 
determined primarily by genetic factors (12) and are 
stable both in healthy adults and in patients with RA (13). 
We have also confirmed the findings of Moore 
et al(1) that IgM-RF is associated with disease activity 
in polyarticular JRA. As we predicted, higher levels of 
CD5+ B cells tended to be associated with the pres- 
ence of IgM-RF as determined by ELISA, although 
this correlation did not reach statistical significance. 
Although it is possible that the presence of IgM-RF 
and the expansion of the CD5+ B cell population may 
be independent events, the occurrence of elevated 
CD5+ B cell levels in diseases associated with IgM- 
RF, but not in other autoimmune diseases (3, suggests 
that the two are related. 
The role of CD5+ B cells in JRA is probably 
linked to the capacity of these cells to produce IgM-RF 
(3,4). These, in turn, may play a direct role in the 
pathophysiology of this and other autoimmune diseases. 
Evidence suggests that IgM-RF alters complement- 
mediated immune complex processing. IgM-RF from 
adults impedes complement-mediated inhibition of im- 
mune precipitation (14), prevents complement binding 
to immune complexes, and prevents the binding of 
those complexes to complement receptors on erythro- 
cytes, while at the same time allowing activation of the 
classical pathway to proceed (15). In addition, recent 
work in our laboratory indicates that sera from chil- 
dren with polyarticular JRA have reduced capacity to 
prevent precipitation of immune complexes, and that 
this is due, in part, to the presence of IgM-RF (Jarvis 
JN et al: unpublished data). 
Thus, it seems reasonable to postulate that the 
expansion of the population of CD5+ B cells is respon- 
sible for the presence of IgM-RF in polyarticular JRA 
and adult RA. Whether this expansion represents 
dysregulation of a separate cell population normally 
CD5+ B CELLS AND IgM-RF IN JRA 207 
kept within strict limits, or is a sign of specific or 
nonspecific B cell activation, remains unknown, but 
we believe answers to these questions will provide 
important insights into the pathophysiology of rheu- 
matic diseases in which rheumatoid factor plays a role. 
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